AbCellera Biologics Inc

Bronze Sponsor

Information

AbCellera partners to discover and develop next-generation therapeutic antibodies. Our team integrates end-to-end capabilities in proprietary immunizations, microfluidics, genomics, computation, and AI to develop innovative strategies that overcome tough challenges and advance discovery programs. We quickly deliver large and diverse panels of high-quality antibodies from any species, including humans.

Social media

Contact details

www.abcellera.com/

Sessions

Amplifying antibody diversity with single-cell screening and immune repertoire sequencing

Monday, March 29, 2021 3:00 PM to 3:20 PM
Antibodies

LIVE Keynote panel discussion: Bispecific discovery and emerging clinical data

Thursday, April 1, 2021 6:40 PM to 7:20 PM
Antibodies

Documents & Links

AbCellera Expands Technology Stack with Acquisition of Trianni for $90 MillionAcquisition enhances AbCellera’s ability to generate large databases of human antibodies for drug discovery programs.
AbCellera’s Platform Contributes to 1st COVID Clinical Trial for MAb TreatmentAbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment
Case Study: Single Chain AntibodiesTo find two rare antibodies, we deployed our deep screening platform and screened 20 million single cells over four days to deeply mine the immune response.
Case Study: Amplifying Antibody DiversitySingle-Cell Screening Combined with Repertoire Sequencing from Humanized Mice

Log in